Delta changes for optimizing clinical specificity and 60-day risk of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome utilizing the ADVIA Centaur TnI-Ultra assay

Fred S. Apple, Stephen W Smith, Lesly A. Pearce, Mary Ann M. Murakami

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Objectives: We determined diagnostic accuracy and risk stratification using delta changes for the cardiac troponin I (cTnI) Centaur Ultra assay for ruling out acute myocardial infarction (AMI) and for risk prediction of adverse events in patients with symptoms of acute coronary syndrome. Design and methods: cTnI was measured on admission and 6-24. h in 371 patients. Optimal deltas (percent change, absolute value of percent change, change, absolute value of change) were determined from ROC curve analysis. Risk stratification was performed for cardiac events and death within 60. days. Results: AMI during hospitalization occurred in 49 patients and endpoints in 11 patients. Diagnostic accuracy by ROC curve was optimal (0.96) using the absolute value of change delta. Diagnostic specificities utilizing the 99th percentile (40. ng/L) for admission and follow-up samples were 84% and 81%, compared to: [90% percent change delta] 89.7%; [66.7% absolute value of percent change delta] 85.5%, [217. ng/L change delta] 99.0% and [55. ng/L absolute value of change delta] 93.7%. All four delta values showed substantially greater risk when the initial cTn value was normal. Conclusions: Utilizing delta cTnI values improves clinical specificity, diagnostic accuracy and risk assessment in patients presenting with symptoms of ACS.

Original languageEnglish (US)
Pages (from-to)711-713
Number of pages3
JournalClinical Biochemistry
Volume45
Issue number10-11
DOIs
StatePublished - Jul 1 2012

Keywords

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Biomarkers
  • Cardiac troponin
  • Delta changes
  • Risk stratification

Fingerprint

Dive into the research topics of 'Delta changes for optimizing clinical specificity and 60-day risk of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome utilizing the ADVIA Centaur TnI-Ultra assay'. Together they form a unique fingerprint.

Cite this